Ушбу иш иқтибос қилган ишлар

55 та иш

Иш: Exploring Cellular Immunotherapy Platforms in Multiple Myeloma

Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto +9
Шарҳ мақола201811 иқтибос
ABI
Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao +3
Шарҳ мақола20236 иқтибос
ABI
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
S. Vincent Rajkumar
Мақола20224 иқтибос
ABI
Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model
Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12
Мақола20213 иқтибос
ABI
CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
Jianjun Chu, Youcai Deng, D.M. Benson +13
Мақола20133 иқтибос
ABI
<i>In vivo</i> kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection
Yan Zhang, Diana L. Wallace, Catherine M. de Lara +8
Мақола20073 иқтибос
ABI
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas, Roberto Salgado, Carsten Denkert +4
Шарҳ мақола20153 иқтибос
ABI
CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.
Joseph D. Malaer, Porunelloor A. Mathew
Мақола20173 иқтибос
ABI
CAR-NK cells: A promising cellular immunotherapy for cancer
Guozhu Xie, Han Dong, Yong Liang +3
Шарҳ мақола20203 иқтибос
ABI
Bispecifics, trispecifics, and other novel immune treatments in myeloma
Guido Lancman, Joshua Richter, Ajai Chari
Шарҳ мақола20203 иқтибос
ABI
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang +2
Шарҳ мақола20213 иқтибос
ABI
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
Ben Creelan, Chao Wang, Jamie K. Teer +23
Мақола20213 иқтибос
ABI
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Zhiwen Fu, Shijun Li, Sifei Han +2
Шарҳ мақола20223 иқтибос
ABI
Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer
Feifei Li, Sheng Liu
Шарҳ мақола20223 иқтибос
ABI
Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy
Cheng Sun, Haoyu Sun, Weihua Xiao +2
Шарҳ мақола20152 иқтибос
ABI
NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma
Cheng Sun, Haoyu Sun, Cai Zhang +1
Шарҳ мақола20142 иқтибос
ABI
Are natural killer cells superior CAR drivers?
Hans Klingemann
Мақола20142 иқтибос
ABI
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma
Sagar Lonial, Jamie Cavenagh
Шарҳ мақола20092 иқтибос
ABI
Personalized Dendritic Cell-Based Tumor Immunotherapy
Nona Janikashvili, Nicolas Larmonier, Emmanuel Katsanis
Шарҳ мақола20092 иқтибос
ABI
Transfection of chimeric anti‐CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells
Hua Jiang, Wenhao Zhang, Peipei Shang +10
Мақола20132 иқтибос
ABI
Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells
Loek J. Eggermont, Leonie E. Paulis, Jurjen Tel +1
Шарҳ мақола20142 иқтибос
ABI
Enhancement of Dendritic Cells as Vaccines for Cancer
Meghan E. Turnis, Cliona M. Rooney
Шарҳ мақола20102 иқтибос
ABI
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
Marina Ratta, Francesco Fagnoni, Antonio Curti +9
Мақола20022 иқтибос
ABI
Regulation of Dendritic Cell Migration to the Draining Lymph Node
Alfonso Martin‐Fontecha, Silvia Sebastiani, Uta E. Höpken +4
Мақола20032 иқтибос
ABI
Targeting B-Cell Maturation Antigen in Multiple Myeloma
Yu‐Tzu Tai, Kenneth C. Anderson
Шарҳ мақола20152 иқтибос
ABI